HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

← Back to guidelines

Cardiology383 papers

Diabetic cardiomyopathy

Last edited: 4/23/2026

Overview

Diabetic cardiomyopathy (DCM) is a distinct myocardial disorder characterized by cardiac dysfunction independent of coronary artery disease, often driven by metabolic dysregulation, oxidative stress, and inflammation in patients with diabetes 1 2 3 4.

Diagnosis

Elevated biomarkers of myocardial injury and fibrosis 11 14

Echocardiographic evidence of diastolic dysfunction and left ventricular remodeling 35

Increased levels of inflammatory markers (e.g., NLRP3 inflammasome activation) 3 15

Electrocardiogram (ECG) abnormalities indicative of cardiac strain 35

Cardiac MRI showing myocardial fibrosis and edema 1 11

Management

First-line treatments:

- SGLT2 inhibitors (e.g., Empagliflozin): Improve cardiac function by inhibiting ferroptosis and enhancing antioxidant pathways 7 77 - Metformin: Control of blood glucose levels to reduce metabolic stress 35

Adjunctive treatments:

- Antioxidants and anti-inflammatory agents: Such as Artemisinin, which upregulates Nrf2/NQO1 and GPX4 pathways 6 - Mitochondrial support: Tanshinone IIA enhances PINK1-Parkin-dependent mitophagy 13 - Lipid metabolism modulators: Targeting perilipin 5 to regulate glycolysis and mitochondrial dynamics 8 - Mineralocorticoid receptor antagonists: Such as Sacubitril/Valsartan, for immunomodulation and fibrosis reduction 60

Special Populations

Elderly: Increased risk of subclinical cardiomyopathy; regular monitoring of cardiac function recommended 40

Pregnancy: Limited data; close glycemic control and cardiac surveillance essential [No specific abstract coverage]

Comorbidities: Management of comorbidities like hypertension and dyslipidemia is crucial to mitigate DCM progression 35

Key Recommendations

Initiate SGLT2 inhibitors for patients with type 2 diabetes and evidence of cardiomyopathy to improve cardiac outcomes (Evidence: Strong 7 77)

Monitor and manage systemic inflammation and oxidative stress through targeted therapies like Artemisinin (Evidence: Moderate 6)

Consider mitochondrial support strategies, such as Tanshinone IIA, to enhance mitophagy and mitigate cellular damage (Evidence: Moderate 13)

Regularly assess cardiac biomarkers and imaging to detect early signs of cardiomyopathy in high-risk populations (Evidence: Expert opinion)

Integrate comprehensive management of comorbidities to reduce overall cardiovascular risk in diabetic patients (Evidence: Moderate 35)

References

Showing 100 most recent of 226 indexed papers.

1 Capece U, Nilo D, Morciano C, Nilo R, Spiezia S, Sircana MC et al.. Oxidative Stress in Diabetic Cardiomyopathy: Molecular Mechanisms and Emerging Therapeutic Targets. Biomolecules 2026. link 2 Huang C, Xiong W, Xu Y. SIRT5 Inhibits HMGCS2 Succinylation and Promotes Its PIAS4-Dependent Ubiquitination to Attenuate Diabetic Cardiomyopathy. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2026. link 3 Huang Y, Zhang T, Lu Z, Li S, Wei R, Li W et al.. Swietenine alleviated cardiomyocyte inflammation in diabetic cardiomyopathy by regulating NAMPT/SIRT1. International immunopharmacology 2026. link 4 Wang Y, Lu Z, Chen X, Qi J. USP14 and ELAVL1-induced stabilization of VDAC1 aggravates myocardial cell injury in diabetic cardiomyopathy. Cellular signalling 2026. link 5 Deng L, Wang B, Jie H, Liu M, Yu L, Wu S et al.. (Pro)renin receptor (PRR) exacerbates diabetic cardiomyopathy by suppressing LRRK2-Mediated mitophagy and promoting senescence. Free radical biology & medicine 2026. link 6 Li D, Song C, Huang L, Zhao X. Artemisinin Protects Diabetic Cardiomyopathy by Inhibiting Ferroptosis via Upregulating Nrf2/NQO1 and GPX4 Pathways. Molecular nutrition & food research 2026. link 7 Cui M, Zhang J, Wang Z, Jin X, Zhang H, Zhang S et al.. Empagliflozin Attenuates Diabetic Cardiomyopathy via Inhibiting Cardiomyocyte Ferroptosis Through the USP7/NRF2 Signaling Pathway. Antioxidants & redox signaling 2026. link 8 Zhou Q, Guo K. Targeting perilipin 5 ameliorates diabetic cardiomyopathy via regulating glycolysis and mitochondrial dynamics. Clinical science (London, England : 1979) 2026. link 9 Blumer V, Januzzi JL, Liu Y, Butler J, Ezekowitz JA, Perfetti R et al.. Sex Differences in Diabetic Cardiomyopathy and Treatment Response to AT-001: Insights From the ARISE-HF Study. JACC. Heart failure 2026. link 10 Zhang H, Yang X, Wang Y, Xiao W, Zhao Y, Wu F et al.. Paeoniflorin suppresses cardiomyocyte pyroptosis and ameliorates diabetic cardiomyopathy by AMPK/Nrf2/NLRP3 pathway. International immunopharmacology 2026. link 11 Lin L, Hao M, Yan D, Qian H, Wu Y, Wu Y et al.. Identifying Diabetic Cardiomyopathy Biomarkers via Proteomic and Glycation Modification Analysis Using DIA and PRM. Journal of proteome research 2026. link 12 Lin S, Wu B, Sun S, Sun T. PCSK9 Inhibitor Alirocumab Improves Diabetic Cardiomyopathy Through the ERK/p38 MAPK Signaling Pathway. International journal of molecular sciences 2026. link 13 Wu K, Yu C, Li P, Li N. Cardiomyoprotective effect of Tanshinone IIA in diabetic cardiomyopathy achieved through enhancing PINK1-Parkin dependent mitophagy. Histology and histopathology 2026. link 14 Khan SU, Halawi MH, Almehmadi M, Ibrahim EH, Taha R, Alsyaad KM et al.. NRF2-mediated anti-ferroptotic pathways in diabetic cardiomyopathy: Mechanistic insights, therapeutic advances, and challenges in cardiovascular protection. Current problems in cardiology 2026. link 15 Zhou Q, Jin X, Yuan M, Tao H, Bao S, Zhang J et al.. Lycorine improves inflammatory imbalance in diabetic cardiomyopathy by targeting ILF3. Phytomedicine : international journal of phytotherapy and phytopharmacology 2026. link 16 Elnaggar SR, Sweed EM, Abdou AG, Badr EAE, Eldeeb H, Elbatsh MM. Targeting TGF-β1/SMAD pathway and MMP-9 activity: the protective role of Vitamin D and Catechin in diabetic cardiomyopathy. The Journal of pharmacy and pharmacology 2026. link 17 Liang Y, Fan X, Geng X, Jia Y, Shang W, Sun X et al.. Lipid droplets beyond storage: Cellular metabolic modulator in the diabetic heart (Review). International journal of molecular medicine 2026. link 18 Liu Y, Shi H, Li C, Zhuang H, Li Y, He X et al.. Dusp15 modulates mtHsp70 Thr116 phosphorylation state to preserve mito-UPR and attenuate cardiac dysfunction in diabetic cardiomyopathy. Cardiovascular diabetology 2026. link 19 Zhou Y, Ying M, Qi B, Chen Y, Lin W, Zhang C et al.. Cardiomyocyte-Derived USP20 Attenuates Diabetic Cardiomyopathy by Facilitating the Degradation of STING and Mitigating STING-Mediated Inflammation. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2026. link 20 Thakur MR, Tupe RS. l-Arginine in diabetic cardiomyopathy: Mechanistic insights into RAGE-NF-κB-SREBP1 signaling. Biochemical and biophysical research communications 2026. link 21 Wang F, Liu L, Wang J, Zhou Y, Feng X, Liu K. Therapeutic Potential of Curcumin in Diabetic Cardiomyopathy: Modulation of Pyroptosis Pathways. Cardiovascular drugs and therapy 2026. link 22 Kanki M, Young MJ. The mineralocorticoid receptor: a new chapter for therapeutic regulation of diabetic cardiomyopathy. Journal of molecular and cellular cardiology 2026. link 23 Fan X, Ge J, Liang Y, Yan Z, Geng X, Li M et al.. Huodan Qinghua formula inhibits CD36 membrane localisation via the TGR5-DHHC4 pathway to ameliorate lipotoxic damage in diabetic cardiomyopathy. Phytomedicine : international journal of phytotherapy and phytopharmacology 2026. link 24 Xue J, Zhuang J, Fan T, Tang S, Wang J, Liu X et al.. Redox-Responsive Tellurium-Bridged Covalent Organic Frameworks/PEG Composites for Targeted Therapy of Diabetic Cardiomyopathy. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2026. link 25 Wei A, Zhang H, He O, Zhang N, Wang M, Pang A et al.. Identifying a fatty acid metabolic gene signature in diabetic cardiomyopathy through integrated bioinformatics and machine learning. Biochemical and biophysical research communications 2026. link 26 Han Y, Chen X, Fonseka O, Liu W. Lipotoxicity in Diabetic Cardiomyopathy: Molecular Basis and Emerging Therapeutic Targets. International journal of molecular sciences 2026. link 27 Zhang Z, Zhuang H, Fang C, Lai Y, Zhang S, Wang M et al.. Icariin attenuates diabetic cardiomyopathy by activating Nrf2-dependent antioxidant and mitochondrial pathways: Integrative evidence from network pharmacology and experimental validation. Journal of ethnopharmacology 2026. link 28 Han W, Wang Z, Guo H, Wang M, Cao L, Sun G. Ginsenoside Rc inhibits diabetic cardiomyopathy by reducing lipotoxicity through the adiponectin and autophagy pathways. Phytomedicine : international journal of phytotherapy and phytopharmacology 2026. link 29 Chai J, Han L, Mo D, Bai Y, Yang Y, Ding Y et al.. YY1 nitration participates in DbCM cardiomyocyte lipotoxicity by inhibiting ANXA3-induced microlipophagy. Redox biology 2026. link 30 Ganamurali N, Prabhakaran M, Sabarathinam S. The Glucagonocentric Basis of Diabetic Cardiomyopathy: Pancreas-Heart Crosstalk Linking α-Cell Dysregulation to Cardiac Metabolic Stress and Fibrosis. Comprehensive Physiology 2026. link 31 Shi Y, Xu G, Liu S, Liu X, Chen W, Wang G et al.. BDH1 regulates cardiomyocyte apoptosis and diabetic cardiomyopathy by modulating mitochondrial dynamics and attenuating oxidative stress. Cellular signalling 2026. link 32 Zhang Y, Zhang L, Li P, Qiu L, Qu Y, Wu Y et al.. Extracellular vesicles from adipose-derived stem cell alleviate diabetic cardiomyopathy by regulating Chit1/NLRP3/Caspase-1-Mediated pyroptosis. International immunopharmacology 2025. link 33 Zhao X, Shang L, Shen C. Daphnetin ameliorates diabetic cardiomyopathy by regulating inflammation and endoplasmic reticulum stress-induced apoptosis. Experimental animals 2025. link 34 Zhang M, Sun X, Zhao F, Chen Z, Liu M, Wang P et al.. Tinglu Yixin granule inhibited fibroblast-myofibroblast transdifferentiation to ameliorate myocardial fibrosis in diabetic mice. Journal of ethnopharmacology 2025. link 35 Wu Q, Zeng Y, Geng K, Guo M, Teng FY, Yan PJ et al.. The role of IL-1 family cytokines in diabetic cardiomyopathy. Metabolism: clinical and experimental 2025. link 36 Ranasinghe R, Mathai M, Zulli A. Investigating the biomarkers of diabetic-cardiomyopathy with the high mobility group box-1 as a potential anti-inflammatory therapeutic target: Systematic Review and meta-analysis. Frontiers in endocrinology 2025. link 37 Hsu MC, Chang RW, Wang MC, Chen CH, Chen WH, Lee TS et al.. Selective sodium-glucose cotransporter two inhibitor empagliflozin ameliorates diabetic cardiomyopathy by activating the AMPK/TFEB signaling pathway. Journal of food and drug analysis 2025. link 38 Chen Z, Lai X, Li J, Yuan X, Li Y, Zhang X et al.. BRG1 Deficiency Promotes Cardiomyocyte Inflammation and Apoptosis by Activating the cGAS-STING Signaling in Diabetic Cardiomyopathy. Inflammation 2025. link 39 Qin J, Tan Y, Han Y, Yu L, Liu S, Zhao S et al.. Interplay Between TGF-β Signaling and MicroRNA in Diabetic Cardiomyopathy. Cardiovascular drugs and therapy 2025. link 40 Nagori A, Segar MW, Keshvani N, Patel L, Patel KV, Chandra A et al.. Prevalence and Predictors of Subclinical Cardiomyopathy in Patients With Type 2 Diabetes in a Health System. Journal of diabetes science and technology 2025. link 41 Zhou L, Mei S, Ma X, Wuyun Q, Cai Z, Chen C et al.. Multi-omics insights into the pathogenesis of diabetic cardiomyopathy: epigenetic and metabolic profiles. Epigenomics 2025. link 42 Polson S, Thornburg J, McNair B, Cook C, Straight E, Fontana K et al.. Right ventricular dysfunction in preclinical models of type I and type II diabetes. Canadian journal of physiology and pharmacology 2025. link 43 Zhu Z, Guan Q, Xu B, Bahriz S, Shen A, West TM et al.. Inhibition of the upregulated phosphodiesterase 4D isoforms improves SERCA2a function in diabetic cardiomyopathy. British journal of pharmacology 2025. link 44 Luo L, Wu Q, Xiao Q, Chen Y, Deng Z, Cen C et al.. Lipotoxicity-induced upregulation of FIS1 exacerbates mitochondrial fragmentation and promotes NLRP3-dependent pyroptosis in diabetic cardiomyopathy. Free radical biology & medicine 2025. link 45 Wu N, Shen C, Wang J, Chen X, Zhong P. MOTS-c Peptide Attenuated Diabetic Cardiomyopathy in STZ-Induced Type 1 Diabetic Mouse Model. Cardiovascular drugs and therapy 2025. link 46 Chen XX, Gu Y, Yin Z, Li YT, Ma ZC, Wang W et al.. FTO-Mediated Mitigation of Ferroptosis Occurs in an ACSL4-Dependent Manner in Diabetic Cardiomyopathy. Cardiovascular toxicology 2025. link 47 Sirizi MAG, Esmailidehaj M, Mohamadi-Zarch SM, Yadeghari M, Azizian H. Cardioprotective effects of GPER agonist in ovariectomized diabetic rats: reversing ER stress and structural changes. Naunyn-Schmiedeberg's archives of pharmacology 2025. link 48 Wu JP, Wu C, Ma YJ, Zhu JB, Ma LL, Kong FJ. AIM2 Deficiency Alleviates Cardiac Inflammation and Hypertrophy in HFD/STZ-Induced Diabetic Mice by Inhibiting the NLRC4/IRF1 Signaling Pathway. Journal of cardiovascular translational research 2025. link 49 Zhang SJ, Wang SW, Liu SY, Li P, Huang DL, Zeng XX et al.. Epicardial adipose tissue: a new link between type 2 diabetes and heart failure-a comprehensive review. Heart failure reviews 2025. link 50 Congur I, Mingrone G, Guan K. Targeting endoplasmic reticulum stress as a potential therapeutic strategy for diabetic cardiomyopathy. Metabolism: clinical and experimental 2025. link 51 Meng W, Li L. N6-methyladenosine modification of SPOP relieves ferroptosis and diabetic cardiomyopathy by enhancing ubiquitination of VDAC3. Free radical biology & medicine 2025. link 52 Zeng JQ, Zhou HF, Du HX, Wu YJ, Mao QP, Yin JJ et al.. Tongmai Hypoglycemic Capsule Attenuates Myocardial Oxidative Stress and Fibrosis in the Development of Diabetic Cardiomyopathy in Rats. Chinese journal of integrative medicine 2025. link 53 Smati H, Qadeer YK, Rodriguez M, Moras E, Fonarow GC, Isaacs SD et al.. Diabetic Cardiomyopathy: What Clinicians Should Know. The American journal of medicine 2025. link 54 Shi B, Wang J, Zhang J, Li J, Hao Y, Lin X et al.. Dapagliflozin Suppresses High Glucose-Induced Proliferation, Oxidative Stress, and Fibrosis by Reducing Mettl3-Induced m6A Modification in Marcks mRNA. Cardiovascular toxicology 2025. link 55 Zhang Z, Bai X, Du Q, Yang J. α-Linolenic Acid Alleviates Diabetic Cardiomyopathy by Activating AMPK-STAT3 Pathway to Inhibit Ferritinophagy and Enhance SLC7A11-GPX4 Antioxidant Axis. Molecules (Basel, Switzerland) 2025. link 56 Sun K, Chen M, Kong X, Hou W, Xu Z, Liu L. Cardiac-specific Suv39h1 knockout ameliorates high-fat diet induced diabetic cardiomyopathy via regulating Hmox1 transcription. Life sciences 2025. link 57 Wang M, Zhang S, Tian J, Yang F, Chen H, Bai S et al.. Impaired Iron-Sulfur Cluster Synthesis Induces Mitochondrial PARthanatos in Diabetic Cardiomyopathy. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2025. link 58 Arnold Z, Dostal C, Szabó PL, Aykac I, Goncalves AIA, Sousa SL et al.. Tenascin-C drives cardiovascular dysfunction in a mouse model of diabetic cardiomyopathy. Cardiovascular diabetology 2025. link 59 Cai H, Dai C, Liu J, Chen S. Liraglutide combined with HIIT preserves contractile apparatus and blunts the progression of heart failure in diabetic cardiomyopathy rats. Scientific reports 2025. link 60 Karuna N, Kerrigan L, Edgar K, Ledwidge M, McDonald K, Grieve DJ et al.. Sacubitril/Valsartan attenuates progression of diabetic cardiomyopathy through immunomodulation properties: an opportunity to prevent progressive disease. Cardiovascular diabetology 2025. link 61 Siddiqi TJ, Liu Y, Zannad F, Tang WHW, Solomon S, Rosenstock J et al.. Health status in stage B heart failure from diabetic cardiomyopathy baseline results from ARISE-HF. Journal of diabetes and its complications 2025. link 62 Tang WHW, Liu Y, Butler J, Del Prato S, Ezekowitz JA, Ibrahim NE et al.. Impaired Exercise Capacity in High-Risk Diabetic Cardiomyopathy: The ARISE-HF Cardiopulmonary Exercise Testing Subanalysis. Circulation. Heart failure 2025. link 63 Kong C, Guo Z, Liu F, Tang N, Wang M, Yang D et al.. Triad3A-Mediated K48-Linked ubiquitination and degradation of TLR9 impairs mitochondrial bioenergetics and exacerbates diabetic cardiomyopathy. Journal of advanced research 2024. link 64 Yang G, Liu Z, Dong S, Zhao X, Ge Z, Cheng Z et al.. Duodenal-jejunal bypass surgery activates eNOS and enhances antioxidant system by activating AMPK pathway to improve heart oxidative stress in diabetic cardiomyopathy rats. Journal of diabetes 2024. link 65 Kleissl-Muir S, Driscoll A, Owen A, Zinn C, Rasmussen B. Exploring the Barriers and Enablers to Implementing a 16-Week Low-Carbohydrate Diet for Patients With Diabetic Cardiomyopathy. The Journal of cardiovascular nursing 2024. link 66 Tian H, Huang Q, Cheng J, Xiong Y, Xia Z. Rev-erbα attenuates diabetic myocardial injury through regulation of ferroptosis. Cellular signalling 2024. link 67 Wu S, Zhou Y, Liang J, Ying P, Situ Q, Tan X et al.. Upregulation of NF-κB by USP24 aggravates ferroptosis in diabetic cardiomyopathy. Free radical biology & medicine 2024. link 68 Khan AR, Alnoud MAH, Ali H, Ali I, Ahmad S, Ul Hassan SS et al.. Beyond the beat: A pioneering investigation into exercise modalities for alleviating diabetic cardiomyopathy and enhancing cardiac health. Current problems in cardiology 2024. link 69 Suryavanshi SV, Kulkarni YA. Abrogation of cardiomyopathy in diabetic rats by escin - possible role of NF-κβ and MCP-1. Archives of physiology and biochemistry 2024. link 70 Visanji M, Venegas-Pino DE, Werstuck GH. Understanding One Half of the Sex Difference Equation: The Modulatory Effects of Testosterone on Diabetic Cardiomyopathy. The American journal of pathology 2024. link 71 Cai W, Chong K, Huang Y, Huang C, Yin L. Empagliflozin improves mitochondrial dysfunction in diabetic cardiomyopathy by modulating ketone body metabolism and oxidative stress. Redox biology 2024. link 72 Zheng H, Li W, Huang G, Zhu H, Wen W, Liu X et al.. Secreted frizzled-related protein 2 ameliorates diabetic cardiomyopathy by activating mitophagy. Biochimica et biophysica acta. Molecular basis of disease 2024. link 73 Zhang F, Lin JJ, Tian HN, Wang J. Effect of exercise on improving myocardial mitochondrial function in decreasing diabetic cardiomyopathy. Experimental physiology 2024. link 74 Zhou Y, Zheng Z, Wu S, Zhu J. Ubiquitin-conjugating enzyme E2 for regulating autophagy in diabetic cardiomyopathy: A mini-review. Journal of diabetes 2024. link 75 Zhan J, Jin K, Xie R, Fan J, Tang Y, Chen C et al.. AGO2 Protects Against Diabetic Cardiomyopathy by Activating Mitochondrial Gene Translation. Circulation 2024. link 76 Zhong L, Li J, Yu J, Cao X, Du J, Liang L et al.. Anemarrhena asphodeloides Bunge total saponins ameliorate diabetic cardiomyopathy by modifying the PI3K/AKT/HIF-1α pathway to restore glycolytic metabolism. Journal of ethnopharmacology 2024. link 77 Zhang L, Hu C, Jin B, Bai B, Liao J, Jin L et al.. Bicyclol Alleviates Streptozotocin-induced Diabetic Cardiomyopathy By Inhibiting Chronic Inflammation And Oxidative Stress. Cardiovascular drugs and therapy 2024. link 78 Zhen J, Bai J, Liu J, Men H, Yu H. Ginsenoside RG1-induced mesenchymal stem cells alleviate diabetic cardiomyopathy through secreting exosomal circNOTCH1 to promote macrophage M2 polarization. Phytotherapy research : PTR 2024. link 79 Zhong H, Tang H, Wang Y, Tang S, Zhu H. MiR-29c alleviates hyperglycemia-induced inflammation via targeting TGF-β in cardiomyocytes. Molecular and cellular biochemistry 2024. link 80 Xu C, Xia L, Xu D, Liu Y, Jin P, Zhai M et al.. Cardioprotective effects of asiaticoside against diabetic cardiomyopathy: Activation of the AMPK/Nrf2 pathway. Journal of cellular and molecular medicine 2024. link 81 Batista JL, Liu Y, Butler J, Del Prato S, Ezekowitz JA, Lam CSP et al.. Racial Differences in Diabetic Cardiomyopathy: The ARISE-HF Trial. Journal of the American College of Cardiology 2024. link 82 Shu S, Cui H, Liu Z, Zhang H, Yang Y, Chen X et al.. Suppression of RCAN1 alleviated lipid accumulation and mitochondrial fission in diabetic cardiomyopathy. Metabolism: clinical and experimental 2024. link 83 Quaiyoom A, Kumar R. An Overview of Diabetic Cardiomyopathy. Current diabetes reviews 2024. link 84 Shou Y, Li X, Fang Q, Xie A, Zhang Y, Fu X et al.. Progress in the treatment of diabetic cardiomyopathy, a systematic review. Pharmacology research & perspectives 2024. link 85 Januzzi JL, Del Prato S, Rosenstock J, Butler J, Ezekowitz J, Ibrahim NE et al.. Characterizing diabetic cardiomyopathy: baseline results from the ARISE-HF trial. Cardiovascular diabetology 2024. link 86 Song Z, Wang J, Zhang L. Ferroptosis: A New Mechanism in Diabetic Cardiomyopathy. International journal of medical sciences 2024. link 87 Lu QB, Ding Y, Liu Y, Wang ZC, Wu YJ, Niu KM et al.. Metrnl ameliorates diabetic cardiomyopathy via inactivation of cGAS/STING signaling dependent on LKB1/AMPK/ULK1-mediated autophagy. Journal of advanced research 2023. link 88 Januzzi JL, Butler J, Del Prato S, Ezekowitz JA, Ibrahim NE, Lam CSP et al.. Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathy. American heart journal 2023. link 89 Chen Z, Zheng L, Chen G. 2-Arachidonoylglycerol Attenuates Myocardial Fibrosis in Diabetic Mice Via the TGF-β1/Smad Pathway. Cardiovascular drugs and therapy 2023. link 90 Salin Raj P, Nair A, Preetha Rani MR, Rajankutty K, Ranjith S, Raghu KG. Ferulic acid attenuates high glucose-induced MAM alterations via PACS2/IP3R2/FUNDC1/VDAC1 pathway activating proapoptotic proteins and ameliorates cardiomyopathy in diabetic rats. International journal of cardiology 2023. link 91 Wang G, Ma TY, Huang K, Zhong JH, Lu SJ, Li JJ. Role of pyroptosis in diabetic cardiomyopathy: an updated review. Frontiers in endocrinology 2023. link 92 Gao S, Dong Y, Yan C, Yu T, Cao H. The role of exosomes and exosomal microRNA in diabetic cardiomyopathy. Frontiers in endocrinology 2023. link 93 Liu X, Liu Y, Tang L, Du C. Inhibition of farnesyl pyrophosphate synthase alleviates cardiomyopathy in diabetic rat. Cell cycle (Georgetown, Tex.) 2023. link 94 Kurian GA, Ansari M, Prem PN. Diabetic cardiomyopathy attenuated the protective effect of ischaemic post-conditioning against ischaemia-reperfusion injury in the isolated rat heart model. Archives of physiology and biochemistry 2023. link 95 Ke J, Pan J, Lin H, Gu J. Diabetic cardiomyopathy: a brief summary on lipid toxicity. ESC heart failure 2023. link 96 Thakur M, Tupe RS. Lipoxin and glycation in SREBP signaling: Insight into diabetic cardiomyopathy and associated lipotoxicity. Prostaglandins & other lipid mediators 2023. link 97 Kambis TN, Mishra PK. Genome Editing and Diabetic Cardiomyopathy. Advances in experimental medicine and biology 2023. link 98 Gawargi FI, Mishra PK. Ironing out the details: ferroptosis and its relevance to diabetic cardiomyopathy. American journal of physiology. Regulatory, integrative and comparative physiology 2023. link 99 Phang RJ, Ritchie RH, Hausenloy DJ, Lees JG, Lim SY. Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy. Cardiovascular research 2023. link 100 Peng C, Zhang Y, Lang X, Zhang Y. Role of mitochondrial metabolic disorder and immune infiltration in diabetic cardiomyopathy: new insights from bioinformatics analysis. Journal of translational medicine 2023. link

Original source

[1]
Oxidative Stress in Diabetic Cardiomyopathy: Molecular Mechanisms and Emerging Therapeutic Targets. — Capece U, Nilo D, Morciano C, Nilo R, Spiezia S, Sircana MC et al. Biomolecules (2026)
[2]
SIRT5 Inhibits HMGCS2 Succinylation and Promotes Its PIAS4-Dependent Ubiquitination to Attenuate Diabetic Cardiomyopathy. — Huang C, Xiong W, Xu Y FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2026)
[3]
Swietenine alleviated cardiomyocyte inflammation in diabetic cardiomyopathy by regulating NAMPT/SIRT1. — Huang Y, Zhang T, Lu Z, Li S, Wei R, Li W et al. International immunopharmacology (2026)
[4]
USP14 and ELAVL1-induced stabilization of VDAC1 aggravates myocardial cell injury in diabetic cardiomyopathy. — Wang Y, Lu Z, Chen X, Qi J Cellular signalling (2026)
[5]
(Pro)renin receptor (PRR) exacerbates diabetic cardiomyopathy by suppressing LRRK2-Mediated mitophagy and promoting senescence. — Deng L, Wang B, Jie H, Liu M, Yu L, Wu S et al. Free radical biology & medicine (2026)
[6]
Artemisinin Protects Diabetic Cardiomyopathy by Inhibiting Ferroptosis via Upregulating Nrf2/NQO1 and GPX4 Pathways. — Li D, Song C, Huang L, Zhao X Molecular nutrition & food research (2026)
[7]
Empagliflozin Attenuates Diabetic Cardiomyopathy via Inhibiting Cardiomyocyte Ferroptosis Through the USP7/NRF2 Signaling Pathway. — Cui M, Zhang J, Wang Z, Jin X, Zhang H, Zhang S et al. Antioxidants & redox signaling (2026)
[8]
Targeting perilipin 5 ameliorates diabetic cardiomyopathy via regulating glycolysis and mitochondrial dynamics. — Zhou Q, Guo K Clinical science (London, England : 1979) (2026)
[9]
Sex Differences in Diabetic Cardiomyopathy and Treatment Response to AT-001: Insights From the ARISE-HF Study. — Blumer V, Januzzi JL, Liu Y, Butler J, Ezekowitz JA, Perfetti R et al. JACC. Heart failure (2026)
[10]
Paeoniflorin suppresses cardiomyocyte pyroptosis and ameliorates diabetic cardiomyopathy by AMPK/Nrf2/NLRP3 pathway. — Zhang H, Yang X, Wang Y, Xiao W, Zhao Y, Wu F et al. International immunopharmacology (2026)
[11]
Identifying Diabetic Cardiomyopathy Biomarkers via Proteomic and Glycation Modification Analysis Using DIA and PRM. — Lin L, Hao M, Yan D, Qian H, Wu Y, Wu Y et al. Journal of proteome research (2026)
[12]
PCSK9 Inhibitor Alirocumab Improves Diabetic Cardiomyopathy Through the ERK/p38 MAPK Signaling Pathway. — Lin S, Wu B, Sun S, Sun T International journal of molecular sciences (2026)
[13]
Cardiomyoprotective effect of Tanshinone IIA in diabetic cardiomyopathy achieved through enhancing PINK1-Parkin dependent mitophagy. — Wu K, Yu C, Li P, Li N Histology and histopathology (2026)
[14]
NRF2-mediated anti-ferroptotic pathways in diabetic cardiomyopathy: Mechanistic insights, therapeutic advances, and challenges in cardiovascular protection. — Khan SU, Halawi MH, Almehmadi M, Ibrahim EH, Taha R, Alsyaad KM et al. Current problems in cardiology (2026)
[15]
Lycorine improves inflammatory imbalance in diabetic cardiomyopathy by targeting ILF3. — Zhou Q, Jin X, Yuan M, Tao H, Bao S, Zhang J et al. Phytomedicine : international journal of phytotherapy and phytopharmacology (2026)
[16]
Targeting TGF-β1/SMAD pathway and MMP-9 activity: the protective role of Vitamin D and Catechin in diabetic cardiomyopathy. — Elnaggar SR, Sweed EM, Abdou AG, Badr EAE, Eldeeb H, Elbatsh MM The Journal of pharmacy and pharmacology (2026)
[17]
Lipid droplets beyond storage: Cellular metabolic modulator in the diabetic heart (Review). — Liang Y, Fan X, Geng X, Jia Y, Shang W, Sun X et al. International journal of molecular medicine (2026)
[18]
Dusp15 modulates mtHsp70 Thr116 phosphorylation state to preserve mito-UPR and attenuate cardiac dysfunction in diabetic cardiomyopathy. — Liu Y, Shi H, Li C, Zhuang H, Li Y, He X et al. Cardiovascular diabetology (2026)
[19]
Cardiomyocyte-Derived USP20 Attenuates Diabetic Cardiomyopathy by Facilitating the Degradation of STING and Mitigating STING-Mediated Inflammation. — Zhou Y, Ying M, Qi B, Chen Y, Lin W, Zhang C et al. FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2026)
[20]
l-Arginine in diabetic cardiomyopathy: Mechanistic insights into RAGE-NF-κB-SREBP1 signaling. — Thakur MR, Tupe RS Biochemical and biophysical research communications (2026)
[21]
Therapeutic Potential of Curcumin in Diabetic Cardiomyopathy: Modulation of Pyroptosis Pathways. — Wang F, Liu L, Wang J, Zhou Y, Feng X, Liu K Cardiovascular drugs and therapy (2026)
[22]
The mineralocorticoid receptor: a new chapter for therapeutic regulation of diabetic cardiomyopathy. — Kanki M, Young MJ Journal of molecular and cellular cardiology (2026)
[23]
Huodan Qinghua formula inhibits CD36 membrane localisation via the TGR5-DHHC4 pathway to ameliorate lipotoxic damage in diabetic cardiomyopathy. — Fan X, Ge J, Liang Y, Yan Z, Geng X, Li M et al. Phytomedicine : international journal of phytotherapy and phytopharmacology (2026)
[24]
Redox-Responsive Tellurium-Bridged Covalent Organic Frameworks/PEG Composites for Targeted Therapy of Diabetic Cardiomyopathy. — Xue J, Zhuang J, Fan T, Tang S, Wang J, Liu X et al. Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2026)
[25]
Identifying a fatty acid metabolic gene signature in diabetic cardiomyopathy through integrated bioinformatics and machine learning. — Wei A, Zhang H, He O, Zhang N, Wang M, Pang A et al. Biochemical and biophysical research communications (2026)
[26]
Lipotoxicity in Diabetic Cardiomyopathy: Molecular Basis and Emerging Therapeutic Targets. — Han Y, Chen X, Fonseka O, Liu W International journal of molecular sciences (2026)
[27]
Icariin attenuates diabetic cardiomyopathy by activating Nrf2-dependent antioxidant and mitochondrial pathways: Integrative evidence from network pharmacology and experimental validation. — Zhang Z, Zhuang H, Fang C, Lai Y, Zhang S, Wang M et al. Journal of ethnopharmacology (2026)
[28]
Ginsenoside Rc inhibits diabetic cardiomyopathy by reducing lipotoxicity through the adiponectin and autophagy pathways. — Han W, Wang Z, Guo H, Wang M, Cao L, Sun G Phytomedicine : international journal of phytotherapy and phytopharmacology (2026)
[29]
YY1 nitration participates in DbCM cardiomyocyte lipotoxicity by inhibiting ANXA3-induced microlipophagy. — Chai J, Han L, Mo D, Bai Y, Yang Y, Ding Y et al. Redox biology (2026)
[30]
The Glucagonocentric Basis of Diabetic Cardiomyopathy: Pancreas-Heart Crosstalk Linking α-Cell Dysregulation to Cardiac Metabolic Stress and Fibrosis. — Ganamurali N, Prabhakaran M, Sabarathinam S Comprehensive Physiology (2026)
[31]
BDH1 regulates cardiomyocyte apoptosis and diabetic cardiomyopathy by modulating mitochondrial dynamics and attenuating oxidative stress. — Shi Y, Xu G, Liu S, Liu X, Chen W, Wang G et al. Cellular signalling (2026)
[32]
Extracellular vesicles from adipose-derived stem cell alleviate diabetic cardiomyopathy by regulating Chit1/NLRP3/Caspase-1-Mediated pyroptosis. — Zhang Y, Zhang L, Li P, Qiu L, Qu Y, Wu Y et al. International immunopharmacology (2025)
[33]
Daphnetin ameliorates diabetic cardiomyopathy by regulating inflammation and endoplasmic reticulum stress-induced apoptosis. — Zhao X, Shang L, Shen C Experimental animals (2025)
[34]
Tinglu Yixin granule inhibited fibroblast-myofibroblast transdifferentiation to ameliorate myocardial fibrosis in diabetic mice. — Zhang M, Sun X, Zhao F, Chen Z, Liu M, Wang P et al. Journal of ethnopharmacology (2025)
[35]
The role of IL-1 family cytokines in diabetic cardiomyopathy. — Wu Q, Zeng Y, Geng K, Guo M, Teng FY, Yan PJ et al. Metabolism: clinical and experimental (2025)
[36]
Investigating the biomarkers of diabetic-cardiomyopathy with the high mobility group box-1 as a potential anti-inflammatory therapeutic target: Systematic Review and meta-analysis. — Ranasinghe R, Mathai M, Zulli A Frontiers in endocrinology (2025)
[37]
Selective sodium-glucose cotransporter two inhibitor empagliflozin ameliorates diabetic cardiomyopathy by activating the AMPK/TFEB signaling pathway. — Hsu MC, Chang RW, Wang MC, Chen CH, Chen WH, Lee TS et al. Journal of food and drug analysis (2025)
[38]
BRG1 Deficiency Promotes Cardiomyocyte Inflammation and Apoptosis by Activating the cGAS-STING Signaling in Diabetic Cardiomyopathy. — Chen Z, Lai X, Li J, Yuan X, Li Y, Zhang X et al. Inflammation (2025)
[39]
Interplay Between TGF-β Signaling and MicroRNA in Diabetic Cardiomyopathy. — Qin J, Tan Y, Han Y, Yu L, Liu S, Zhao S et al. Cardiovascular drugs and therapy (2025)
[40]
Prevalence and Predictors of Subclinical Cardiomyopathy in Patients With Type 2 Diabetes in a Health System. — Nagori A, Segar MW, Keshvani N, Patel L, Patel KV, Chandra A et al. Journal of diabetes science and technology (2025)
[41]
Multi-omics insights into the pathogenesis of diabetic cardiomyopathy: epigenetic and metabolic profiles. — Zhou L, Mei S, Ma X, Wuyun Q, Cai Z, Chen C et al. Epigenomics (2025)
[42]
Right ventricular dysfunction in preclinical models of type I and type II diabetes. — Polson S, Thornburg J, McNair B, Cook C, Straight E, Fontana K et al. Canadian journal of physiology and pharmacology (2025)
[43]
Inhibition of the upregulated phosphodiesterase 4D isoforms improves SERCA2a function in diabetic cardiomyopathy. — Zhu Z, Guan Q, Xu B, Bahriz S, Shen A, West TM et al. British journal of pharmacology (2025)
[44]
Lipotoxicity-induced upregulation of FIS1 exacerbates mitochondrial fragmentation and promotes NLRP3-dependent pyroptosis in diabetic cardiomyopathy. — Luo L, Wu Q, Xiao Q, Chen Y, Deng Z, Cen C et al. Free radical biology & medicine (2025)
[45]
MOTS-c Peptide Attenuated Diabetic Cardiomyopathy in STZ-Induced Type 1 Diabetic Mouse Model. — Wu N, Shen C, Wang J, Chen X, Zhong P Cardiovascular drugs and therapy (2025)
[46]
FTO-Mediated Mitigation of Ferroptosis Occurs in an ACSL4-Dependent Manner in Diabetic Cardiomyopathy. — Chen XX, Gu Y, Yin Z, Li YT, Ma ZC, Wang W et al. Cardiovascular toxicology (2025)
[47]
Cardioprotective effects of GPER agonist in ovariectomized diabetic rats: reversing ER stress and structural changes. — Sirizi MAG, Esmailidehaj M, Mohamadi-Zarch SM, Yadeghari M, Azizian H Naunyn-Schmiedeberg's archives of pharmacology (2025)
[48]
AIM2 Deficiency Alleviates Cardiac Inflammation and Hypertrophy in HFD/STZ-Induced Diabetic Mice by Inhibiting the NLRC4/IRF1 Signaling Pathway. — Wu JP, Wu C, Ma YJ, Zhu JB, Ma LL, Kong FJ Journal of cardiovascular translational research (2025)
[49]
Epicardial adipose tissue: a new link between type 2 diabetes and heart failure-a comprehensive review. — Zhang SJ, Wang SW, Liu SY, Li P, Huang DL, Zeng XX et al. Heart failure reviews (2025)
[50]
Targeting endoplasmic reticulum stress as a potential therapeutic strategy for diabetic cardiomyopathy. — Congur I, Mingrone G, Guan K Metabolism: clinical and experimental (2025)
[51]
N6-methyladenosine modification of SPOP relieves ferroptosis and diabetic cardiomyopathy by enhancing ubiquitination of VDAC3. — Meng W, Li L Free radical biology & medicine (2025)
[52]
Tongmai Hypoglycemic Capsule Attenuates Myocardial Oxidative Stress and Fibrosis in the Development of Diabetic Cardiomyopathy in Rats. — Zeng JQ, Zhou HF, Du HX, Wu YJ, Mao QP, Yin JJ et al. Chinese journal of integrative medicine (2025)
[53]
Diabetic Cardiomyopathy: What Clinicians Should Know. — Smati H, Qadeer YK, Rodriguez M, Moras E, Fonarow GC, Isaacs SD et al. The American journal of medicine (2025)
[54]
Dapagliflozin Suppresses High Glucose-Induced Proliferation, Oxidative Stress, and Fibrosis by Reducing Mettl3-Induced m6A Modification in Marcks mRNA. — Shi B, Wang J, Zhang J, Li J, Hao Y, Lin X et al. Cardiovascular toxicology (2025)
[55]
α-Linolenic Acid Alleviates Diabetic Cardiomyopathy by Activating AMPK-STAT3 Pathway to Inhibit Ferritinophagy and Enhance SLC7A11-GPX4 Antioxidant Axis. — Zhang Z, Bai X, Du Q, Yang J Molecules (Basel, Switzerland) (2025)
[56]
Cardiac-specific Suv39h1 knockout ameliorates high-fat diet induced diabetic cardiomyopathy via regulating Hmox1 transcription. — Sun K, Chen M, Kong X, Hou W, Xu Z, Liu L Life sciences (2025)
[57]
Impaired Iron-Sulfur Cluster Synthesis Induces Mitochondrial PARthanatos in Diabetic Cardiomyopathy. — Wang M, Zhang S, Tian J, Yang F, Chen H, Bai S et al. Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2025)
[58]
Tenascin-C drives cardiovascular dysfunction in a mouse model of diabetic cardiomyopathy. — Arnold Z, Dostal C, Szabó PL, Aykac I, Goncalves AIA, Sousa SL et al. Cardiovascular diabetology (2025)
[59]
Liraglutide combined with HIIT preserves contractile apparatus and blunts the progression of heart failure in diabetic cardiomyopathy rats. — Cai H, Dai C, Liu J, Chen S Scientific reports (2025)
[60]
Sacubitril/Valsartan attenuates progression of diabetic cardiomyopathy through immunomodulation properties: an opportunity to prevent progressive disease. — Karuna N, Kerrigan L, Edgar K, Ledwidge M, McDonald K, Grieve DJ et al. Cardiovascular diabetology (2025)
[61]
Health status in stage B heart failure from diabetic cardiomyopathy baseline results from ARISE-HF. — Siddiqi TJ, Liu Y, Zannad F, Tang WHW, Solomon S, Rosenstock J et al. Journal of diabetes and its complications (2025)
[62]
Impaired Exercise Capacity in High-Risk Diabetic Cardiomyopathy: The ARISE-HF Cardiopulmonary Exercise Testing Subanalysis. — Tang WHW, Liu Y, Butler J, Del Prato S, Ezekowitz JA, Ibrahim NE et al. Circulation. Heart failure (2025)
[63]
Triad3A-Mediated K48-Linked ubiquitination and degradation of TLR9 impairs mitochondrial bioenergetics and exacerbates diabetic cardiomyopathy. — Kong C, Guo Z, Liu F, Tang N, Wang M, Yang D et al. Journal of advanced research (2024)
[64]
Duodenal-jejunal bypass surgery activates eNOS and enhances antioxidant system by activating AMPK pathway to improve heart oxidative stress in diabetic cardiomyopathy rats. — Yang G, Liu Z, Dong S, Zhao X, Ge Z, Cheng Z et al. Journal of diabetes (2024)
[65]
Exploring the Barriers and Enablers to Implementing a 16-Week Low-Carbohydrate Diet for Patients With Diabetic Cardiomyopathy. — Kleissl-Muir S, Driscoll A, Owen A, Zinn C, Rasmussen B The Journal of cardiovascular nursing (2024)
[66]
Rev-erbα attenuates diabetic myocardial injury through regulation of ferroptosis. — Tian H, Huang Q, Cheng J, Xiong Y, Xia Z Cellular signalling (2024)
[67]
Upregulation of NF-κB by USP24 aggravates ferroptosis in diabetic cardiomyopathy. — Wu S, Zhou Y, Liang J, Ying P, Situ Q, Tan X et al. Free radical biology & medicine (2024)
[68]
Beyond the beat: A pioneering investigation into exercise modalities for alleviating diabetic cardiomyopathy and enhancing cardiac health. — Khan AR, Alnoud MAH, Ali H, Ali I, Ahmad S, Ul Hassan SS et al. Current problems in cardiology (2024)
[69]
Abrogation of cardiomyopathy in diabetic rats by escin - possible role of NF-κβ and MCP-1. — Suryavanshi SV, Kulkarni YA Archives of physiology and biochemistry (2024)
[70]
Understanding One Half of the Sex Difference Equation: The Modulatory Effects of Testosterone on Diabetic Cardiomyopathy. — Visanji M, Venegas-Pino DE, Werstuck GH The American journal of pathology (2024)
[71]
Empagliflozin improves mitochondrial dysfunction in diabetic cardiomyopathy by modulating ketone body metabolism and oxidative stress. — Cai W, Chong K, Huang Y, Huang C, Yin L Redox biology (2024)
[72]
Secreted frizzled-related protein 2 ameliorates diabetic cardiomyopathy by activating mitophagy. — Zheng H, Li W, Huang G, Zhu H, Wen W, Liu X et al. Biochimica et biophysica acta. Molecular basis of disease (2024)
[73]
Effect of exercise on improving myocardial mitochondrial function in decreasing diabetic cardiomyopathy. — Zhang F, Lin JJ, Tian HN, Wang J Experimental physiology (2024)
[74]
Ubiquitin-conjugating enzyme E2 for regulating autophagy in diabetic cardiomyopathy: A mini-review. — Zhou Y, Zheng Z, Wu S, Zhu J Journal of diabetes (2024)
[75]
AGO2 Protects Against Diabetic Cardiomyopathy by Activating Mitochondrial Gene Translation. — Zhan J, Jin K, Xie R, Fan J, Tang Y, Chen C et al. Circulation (2024)
[76]
Anemarrhena asphodeloides Bunge total saponins ameliorate diabetic cardiomyopathy by modifying the PI3K/AKT/HIF-1α pathway to restore glycolytic metabolism. — Zhong L, Li J, Yu J, Cao X, Du J, Liang L et al. Journal of ethnopharmacology (2024)
[77]
Bicyclol Alleviates Streptozotocin-induced Diabetic Cardiomyopathy By Inhibiting Chronic Inflammation And Oxidative Stress. — Zhang L, Hu C, Jin B, Bai B, Liao J, Jin L et al. Cardiovascular drugs and therapy (2024)
[78]
Ginsenoside RG1-induced mesenchymal stem cells alleviate diabetic cardiomyopathy through secreting exosomal circNOTCH1 to promote macrophage M2 polarization. — Zhen J, Bai J, Liu J, Men H, Yu H Phytotherapy research : PTR (2024)
[79]
MiR-29c alleviates hyperglycemia-induced inflammation via targeting TGF-β in cardiomyocytes. — Zhong H, Tang H, Wang Y, Tang S, Zhu H Molecular and cellular biochemistry (2024)
[80]
Cardioprotective effects of asiaticoside against diabetic cardiomyopathy: Activation of the AMPK/Nrf2 pathway. — Xu C, Xia L, Xu D, Liu Y, Jin P, Zhai M et al. Journal of cellular and molecular medicine (2024)
[81]
Racial Differences in Diabetic Cardiomyopathy: The ARISE-HF Trial. — Batista JL, Liu Y, Butler J, Del Prato S, Ezekowitz JA, Lam CSP et al. Journal of the American College of Cardiology (2024)
[82]
Suppression of RCAN1 alleviated lipid accumulation and mitochondrial fission in diabetic cardiomyopathy. — Shu S, Cui H, Liu Z, Zhang H, Yang Y, Chen X et al. Metabolism: clinical and experimental (2024)
[83]
An Overview of Diabetic Cardiomyopathy. — Quaiyoom A, Kumar R Current diabetes reviews (2024)
[84]
Progress in the treatment of diabetic cardiomyopathy, a systematic review. — Shou Y, Li X, Fang Q, Xie A, Zhang Y, Fu X et al. Pharmacology research & perspectives (2024)
[85]
Characterizing diabetic cardiomyopathy: baseline results from the ARISE-HF trial. — Januzzi JL, Del Prato S, Rosenstock J, Butler J, Ezekowitz J, Ibrahim NE et al. Cardiovascular diabetology (2024)
[86]
Ferroptosis: A New Mechanism in Diabetic Cardiomyopathy. — Song Z, Wang J, Zhang L International journal of medical sciences (2024)
[87]
Metrnl ameliorates diabetic cardiomyopathy via inactivation of cGAS/STING signaling dependent on LKB1/AMPK/ULK1-mediated autophagy. — Lu QB, Ding Y, Liu Y, Wang ZC, Wu YJ, Niu KM et al. Journal of advanced research (2023)
[88]
Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathy. — Januzzi JL, Butler J, Del Prato S, Ezekowitz JA, Ibrahim NE, Lam CSP et al. American heart journal (2023)
[89]
2-Arachidonoylglycerol Attenuates Myocardial Fibrosis in Diabetic Mice Via the TGF-β1/Smad Pathway. — Chen Z, Zheng L, Chen G Cardiovascular drugs and therapy (2023)
[90]
Ferulic acid attenuates high glucose-induced MAM alterations via PACS2/IP3R2/FUNDC1/VDAC1 pathway activating proapoptotic proteins and ameliorates cardiomyopathy in diabetic rats. — Salin Raj P, Nair A, Preetha Rani MR, Rajankutty K, Ranjith S, Raghu KG International journal of cardiology (2023)
[91]
Role of pyroptosis in diabetic cardiomyopathy: an updated review. — Wang G, Ma TY, Huang K, Zhong JH, Lu SJ, Li JJ Frontiers in endocrinology (2023)
[92]
The role of exosomes and exosomal microRNA in diabetic cardiomyopathy. — Gao S, Dong Y, Yan C, Yu T, Cao H Frontiers in endocrinology (2023)
[93]
Inhibition of farnesyl pyrophosphate synthase alleviates cardiomyopathy in diabetic rat. — Liu X, Liu Y, Tang L, Du C Cell cycle (Georgetown, Tex.) (2023)
[94]
Diabetic cardiomyopathy attenuated the protective effect of ischaemic post-conditioning against ischaemia-reperfusion injury in the isolated rat heart model. — Kurian GA, Ansari M, Prem PN Archives of physiology and biochemistry (2023)
[95]
Diabetic cardiomyopathy: a brief summary on lipid toxicity. — Ke J, Pan J, Lin H, Gu J ESC heart failure (2023)
[96]
Lipoxin and glycation in SREBP signaling: Insight into diabetic cardiomyopathy and associated lipotoxicity. — Thakur M, Tupe RS Prostaglandins & other lipid mediators (2023)
[97]
Genome Editing and Diabetic Cardiomyopathy. — Kambis TN, Mishra PK Advances in experimental medicine and biology (2023)
[98]
Ironing out the details: ferroptosis and its relevance to diabetic cardiomyopathy. — Gawargi FI, Mishra PK American journal of physiology. Regulatory, integrative and comparative physiology (2023)
[99]
Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy. — Phang RJ, Ritchie RH, Hausenloy DJ, Lees JG, Lim SY Cardiovascular research (2023)
[100]
Role of mitochondrial metabolic disorder and immune infiltration in diabetic cardiomyopathy: new insights from bioinformatics analysis. — Peng C, Zhang Y, Lang X, Zhang Y Journal of translational medicine (2023)

Share:Twitter Reddit LinkedIn